相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC
Fang Yang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
PROTAC targeted protein degraders: the past is prologue
Miklos Bekes et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations
Chuan Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Highly Potent, Selective, Biostable, and Cell-Permeable Cyclic D-Peptide for Dual-Targeting Therapy of Lung Cancer
Yunjiang Zhou et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2022)
A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.
Jian Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Investigation of KRAS G12C inhibitor JAB-21822 as a single agent and in combination with SHP2 inhibitor JAB-3312 in preclinical cancer models
P. Wang et al.
ANNALS OF ONCOLOGY (2022)
Target protein localization and its impact on PROTAC-mediated degradation
Luke M. Simpson et al.
CELL CHEMICAL BIOLOGY (2022)
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
Geoffrey Shapiro et al.
INVESTIGATIONAL NEW DRUGS (2021)
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H. Hofmann et al.
CANCER DISCOVERY (2021)
Proteasome interaction with ubiquitinated substrates: from mechanisms to therapies
Xiang Chen et al.
FEBS JOURNAL (2021)
Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
Soonsil Hyun et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins
Ryosuke Shirasaki et al.
CELL REPORTS (2021)
Mutant-selective degradation by BRAF-targeting PROTACs
Shanique Alabi et al.
NATURE COMMUNICATIONS (2021)
Advances in targeting 'undruggable' transcription factors with small molecules
Matthew J. Henley et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Clinical Acquired Resistance to KRASG12C Inhibition through a novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation
Noritaka Tanaka et al.
CANCER DISCOVERY (2021)
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?
Federica Martorana et al.
FRONTIERS IN PHARMACOLOGY (2021)
Targeting Son of Sevenless 1: The pacemaker of KRAS
Dirk Kessler et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2021)
Acquired Resistance to KRASG12C Inhibition in Cancer
M. M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The role of reversible and irreversible covalent chemistry in targeted protein degradation
Hannah Kiely-Collins et al.
CELL CHEMICAL BIOLOGY (2021)
Inhibition of Nonfunctional Ras
Ruth Nussinov et al.
CELL CHEMICAL BIOLOGY (2021)
Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system
Ke Ma et al.
NEURAL REGENERATION RESEARCH (2021)
PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance
Xiuyun Sun et al.
BIOCHEMISTRY (2020)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
George M. Burslem et al.
CELL (2020)
Design, Synthesis, and Biological Evaluation of MEK PROTACs
Stefan Vollmer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma
Manali Dimri et al.
CANCERS (2020)
Discovery of Selective Small Molecule Degraders of BRAF-V600E
Xiao-Ran Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein
Mingliang Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Emerging New Concepts of Degrader Technologies
Yu Ding et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
Vito Amodio et al.
CANCER DISCOVERY (2020)
Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
Michael J. Bond et al.
ACS CENTRAL SCIENCE (2020)
Discovery of Novel PDEd Degraders for the Treatment of KRAS Mutant Colorectal Cancer
Junfei Cheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Functional characterization of a PROTAC directed against BRAF mutant V600E
Ganna Posternak et al.
NATURE CHEMICAL BIOLOGY (2020)
RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf
Ziyang Zhang et al.
ACS CENTRAL SCIENCE (2020)
Targeting Endogenous K-RAS for Degradation through the Affinity-Directed Protein Missile System
Sascha Roth et al.
CELL CHEMICAL BIOLOGY (2020)
Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling
Inchul You et al.
CELL CHEMICAL BIOLOGY (2020)
Exploring Targeted Degradation Strategy for Oncogenic KRASG12C
Mei Zeng et al.
CELL CHEMICAL BIOLOGY (2020)
Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2
Alina Mares et al.
COMMUNICATIONS BIOLOGY (2020)
Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
Yonghui Sun et al.
LEUKEMIA (2019)
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Drugging an undruggable pocket on KRAS
Dirk Kessler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
RAS: Striking at the Core of the Oncogenic Circuitry
Ryan C. Gimple et al.
FRONTIERS IN ONCOLOGY (2019)
Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader
Jieli Wei et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
Xin Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Pharmacological targeting of RAS: Recent success with direct inhibitors
John P. O'Bryan
PHARMACOLOGICAL RESEARCH (2019)
SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors
Tamer A. Ahmed et al.
CELL REPORTS (2019)
PROTAC-Mediated Degradation of KRAS Protein for Anticancer Therapeutics
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2019)
Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome
Kim M. Keppler-Noreuil et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2019)
Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1
Andrew P. Crew et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
Ian Churcher
JOURNAL OF MEDICINAL CHEMISTRY (2018)
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Chiara Ambrogio et al.
CELL (2018)
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Francisco Sanchez-Vega et al.
CELL (2018)
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
Yonghui Sun et al.
CELL RESEARCH (2018)
The dTAG system for immediate and target-specific protein degradation
Behnam Nabet et al.
NATURE CHEMICAL BIOLOGY (2018)
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Dietrich A. Ruess et al.
NATURE MEDICINE (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS
Timothy R. Hodges et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
Camilo E. Quevedo et al.
NATURE COMMUNICATIONS (2018)
Therapeutic strategies to target RAS-mutant cancers
Meagan B. Ryan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
George M. Burslem et al.
CELL CHEMICAL BIOLOGY (2018)
Structural basis of PROTAC cooperative recognition for selective protein degradation
Morgan S. Gadd et al.
NATURE CHEMICAL BIOLOGY (2017)
Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration
Seung-Min Shin et al.
NATURE COMMUNICATIONS (2017)
Recent progress towards clinically relevant ATP-competitive Akt inhibitors
Bayard R. Huck et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Influence of isoform-specific Ras lipidation motifs on protein partitioning and dynamics in model membrane systems of various complexity
Nelli Erwin et al.
BIOLOGICAL CHEMISTRY (2017)
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton et al.
CELL (2017)
A PDE6δ-KRas Inhibitor Chemotype with up to Seven H-Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2
Pablo Martin-Gago et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)
RAS isoforms and mutations in cancer at a glance
G. Aaron Hobbs et al.
JOURNAL OF CELL SCIENCE (2016)
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
Jorge Garcia Fortanet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi et al.
LANCET (2016)
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen et al.
NATURE (2016)
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Jonathan M. L. Ostrem et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
Kristel Kemper et al.
CELL REPORTS (2016)
Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
Honorine Lebraud et al.
ACS CENTRAL SCIENCE (2016)
TBK1 inhibitors: a review of patent literature (2011-2014)
Tao Yu et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2015)
The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles of effective cancer therapy
Zutao Yu et al.
FUTURE MEDICINAL CHEMISTRY (2015)
Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
Khanh Do et al.
INVESTIGATIONAL NEW DRUGS (2015)
Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices
Elizaveta S. Leshchiner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
Severa Bunda et al.
NATURE COMMUNICATIONS (2015)
Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation
Neroshan Thevakumaran et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)
Small-Molecule Control of Intracellular Protein Levels through Modulation of the Ubiquitin Proteasome System
Dennis L. Buckley et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
PI3K/AKT signaling pathway and cancer: an updated review
Miriam Martini et al.
ANNALS OF MEDICINE (2014)
Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
Piro Lito et al.
CANCER CELL (2014)
KRas Localizes to the Plasma Membrane by Spatial Cycles of Solubilization, Trapping and Vesicular Transport
Malte Schmick et al.
CELL (2014)
RAS interaction with P13K p110α is required for tumor-induced angiogenesis
Miguel Manuel Murillo et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Structure of the DDBI-CRBN E3 ubiquitin ligase in complex with thalidomide
Eric S. Fischer et al.
NATURE (2014)
The clinical development of MEK inhibitors
Yujie Zhao et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
Michael C. Burns et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
Zehua Zhu et al.
CANCER DISCOVERY (2014)
Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
Klaus Okkenhaug
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction
Fumi Shima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1a
Dennis L. Buckley et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKε kinases
Edward G. McIver et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
Haoqiang Ying et al.
CELL (2012)
The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins
Anchal Chandra et al.
NATURE CELL BIOLOGY (2012)
Regulating the regulator: post-translational modification of RAS
Ian M. Ahearn et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
Till Maurer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Analysis of Binding Site Hot Spots on the Surface of Ras GTPase
Greg Buhrman et al.
JOURNAL OF MOLECULAR BIOLOGY (2011)
Integrating Cardiac PIP3 and cAMP Signaling through a PKA Anchoring Function of p110γ
Alessia Perino et al.
MOLECULAR CELL (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Novel Allosteric Sites on Ras for Lead Generation
Barry J. Grant et al.
PLOS ONE (2011)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
The emerging mechanisms of isoform-specific PI3K signalling
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Ras membrane orientation and nanodomain localization generate isoform diversity
Daniel Abankwa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
How ERK1/2 activation controls cell proliferation and cell death is subcellular localization the answer?
Yohannes Mebratu et al.
CELL CYCLE (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
Christine A. Pratilas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Clinical and biological significance of RAS mutations in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2008)
Mapping the nucleotide and isoform-dependent structural and dynamical features of ras proteins
Alemayehu A. Gorfe et al.
STRUCTURE (2008)
Control of Axonal Growth and Regeneration of Sensory Neurons by the p110δ PI 3-Kinase
Britta J. Eickholt et al.
PLOS ONE (2007)
The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition
S. Meloche et al.
ONCOGENE (2007)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor sprouty
H Hanafusa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Signal transduction - The guanine nucleotide-binding switch in three dimensions
IR Vetter et al.
SCIENCE (2001)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Ras proteins in the control of the cell cycle and cell differentiation
P Crespo et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2000)
分享论文
